SCHEMBL7144451

SCHEMBL7144451

COc1ccc(-c2ccccc2)n2nc(NC(=O)c3ccccc3F)nc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 5/20 0.48
JAK1 P23458 1/20 0.47
MAPT P10636 4/20 0.47
NPC1 O15118 4/20 0.47
RAB9A P51151 3/20 0.47
POLB P06746 2/20 0.46
BLM P54132 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
KDM4E B2RXH2 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HPGD P15428 1/20 0.46
KMT2A Q03164 3/20 0.46
PIM1 P11309 2/20 0.45
LIMK1 P53667 1/20 0.45
ADORA3 P0DMS8 1/20 0.44
ADORA2A P29274 1/20 0.44
ADORA1 P30542 1/20 0.44
LMNA P02545 1/20 0.44
ALDH1A1 P00352 1/20 0.43
MAPK13 O15264 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7152468 0.88 PDE4D (0.48) PDE4DMAPTNPC1RAB9APOLB
SCHEMBL7145323 0.88 PDE4D (0.48) PDE4DMAPTNPC1RAB9APOLB
SCHEMBL6870164 0.86 KDM4E (0.58) PDE4DMAPTNPC1RAB9APOLB
SCHEMBL7039193 0.85 LMNA (0.61) PDE4DMAPTNPC1RAB9ARXFP1
SCHEMBL7146900 0.83 PDE4D (0.50) PDE4DMAPTNPC1RAB9APOLB
SCHEMBL7140763 0.82 MAPT (0.68) PDE4DJAK1MAPTNPC1RAB9A
SCHEMBL7042283 0.81 MAPT (0.56) PDE4DMAPTNPC1RAB9ARXFP1
SCHEMBL7149095 0.80 MAPT (0.54) PDE4DJAK1MAPTNPC1RAB9A
SCHEMBL7148767 0.80 KDM4E (0.54) PDE4DMAPTNPC1RAB9ARXFP1
SCHEMBL7146644 0.80 SMN1; SMN2 (0.53) PDE4DMAPTNPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6514989-B1 Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor HOFFMANN-LA ROCHE INC. 2003-02-04 US disclosed
US-6514989-B1 Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor HOFFMANN-LA ROCHE INC. 2003-02-04 US disclosed
US-6514989-B1 Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor HOFFMANN-LA ROCHE INC. 2003-02-04 US disclosed